BMBerta Renedo Miró

Berta Renedo Miró

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Berta Renedo Miró has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimizing Posaconazole Suspension Prophylaxis in Pediatric Patients: The Key Role of Therapeutic Drug Monitoring

    by Maria Álvarez de Toledo, Maria Blanca Guembe Zabaleta, Laura Barenblit-Mas, María Larrosa-García, Aurora Fernandez-Polo, Laura Castellote, Laura Roig-Soria, Berta Renedo Miró, Maria Teresa Martín Gómez, Laura Alonso García, et al.

    Background: Posaconazole suspension is widely used for the prophylaxis of breakthrough invasive fungal infections in high-risk children. Due to its low bioavailability and high pharmacokinetic variability, therapeutic drug monitoring (TDM) is recommended. Objectives: To describe prophylactic posaconazole suspension TDM in children, evaluate its effectiveness and investigate factors influencing its pharmacokinetics. Methods: Retrospective observational study from 2017–2023, including consecutive patients trough ]). Results: Seventy-one patients were included (median age 4.8 [interquartile range, IQR 2.4–8.9] years). The most frequent underlying condition was inborn errors of immunity (23, 32.4%); 55 patients (77.5%) had undergone hematopoietic stem-cell transplantation. Out of 373 C trough , 178 (47.7%) were within the therapeutic range and 187 (50.1%) were subtherapeutic. The median posaconazole dose was significantly higher in patients under 2 (17.4 [IQR 12.6–23.7] mg/kg/day vs. 13.4 [IQR 12.0–18.4] mg/kg/day, P < 0.001). Nausea/vomiting (odds ratio [OR] 4.89; 95% confidence interval 2.09–11.44; P = 0.0003) and concomitant proton pump inhibitor use (OR 3.03; 95% confidence interval 1.15–7.95; P = 0.0248) were significantly associated with subtherapeutic C trough . Proven breakthrough invasive fungal infections occurred in 3 (4.2%) patients, with no statistically significant difference in subtherapeutic C trough values compared with the rest of the cohort ( P = 0.128). Toxicity was not related to supratherapeutic C trough . Conclusions: Our study highlights the importance of TDM in pediatric patients receiving posaconazole suspension, particularly those with risk factors associated with subtherapeutic C trough . Although further studies are needed to define the optimal dosage in children under 2, our findings suggest that these patients should receive at least 15 mg/kg/day.

  • Open Access

    European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies

    by Juan Morote, Berta Miró, Lucas Regis, François Cousin, Patrick Duflot, Philippe Kolh, Alice Andalò, Nicola Gentili, Filippo Merloni, Andrea Prochowski Iamurri, et al.